Hancock Jaffe Laboratories (NASDAQ: HJLI) is one of 124 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare Hancock Jaffe Laboratories to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, valuation, risk and earnings.


This table compares Hancock Jaffe Laboratories and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Hancock Jaffe Laboratories -5,161.19% -302.90% -182.37%
Hancock Jaffe Laboratories Competitors -805.60% -110.32% -21.95%

Analyst Ratings

This is a summary of current ratings for Hancock Jaffe Laboratories and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hancock Jaffe Laboratories 0 0 0 0 N/A
Hancock Jaffe Laboratories Competitors 895 3008 5177 265 2.51

As a group, “Surgical & medical instruments” companies have a potential upside of 15.68%. Given Hancock Jaffe Laboratories’ peers higher probable upside, analysts clearly believe Hancock Jaffe Laboratories has less favorable growth aspects than its peers.

Valuation and Earnings

This table compares Hancock Jaffe Laboratories and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Hancock Jaffe Laboratories $190,000.00 -$13.04 million -0.51
Hancock Jaffe Laboratories Competitors $1.46 billion $148.50 million 52.86

Hancock Jaffe Laboratories’ peers have higher revenue and earnings than Hancock Jaffe Laboratories. Hancock Jaffe Laboratories is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

1.1% of Hancock Jaffe Laboratories shares are held by institutional investors. Comparatively, 50.5% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.3% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Hancock Jaffe Laboratories peers beat Hancock Jaffe Laboratories on 9 of the 9 factors compared.

Hancock Jaffe Laboratories Company Profile

Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.

Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.